# ZyVersa Therapeutics Inc. (ZVSA)

Source: https://www.quantisnow.com/company/ZVSA
Generated: 2026-11-06T09:15:48.573Z

- Ticker: ZVSA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2022
- SEC CIK: 0001859007

## Latest ZVSA news and filings

- 2026-07-16 21:00 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-other-events-6640061)
- 2026-07-10 20:30 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-leadership-update-other-6634255)
- 2026-05-13 20:55 UTC [Earnings] [ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/zyversa-therapeutics-reports-first-quarter-2026-financial-results-and-provides-6551470)
- 2026-05-13 20:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-zyversa-therapeutics-inc-6551416)
- 2026-03-31 21:05 UTC [Earnings] [ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/zyversa-therapeutics-reports-full-year-2025-financial-results-and-provides-6479875)
- 2026-03-31 20:54 UTC [SEC Form 10-K] [SEC Form 10-K filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-zyversa-therapeutics-inc-6479776)
- 2026-03-05 21:05 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6432352)
- 2025-12-03 21:15 UTC [SEC Form 8-K] [SEC Form 8-K filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-zyversa-therapeutics-inc-6301643)
- 2025-11-19 21:25 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6287112)
- 2025-11-19 21:20 UTC [Earnings] [ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results](https://www.quantisnow.com/insight/zyversa-therapeutics-reports-third-quarter-2025-financial-results-6287041)
- 2025-11-19 21:16 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-zyversa-therapeutics-inc-6287038)
- 2025-11-14 22:00 UTC [SEC Form NT 10-Q filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-zyversa-therapeutics-inc-6281272)
- 2025-10-15 20:30 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-leadership-update-6234189)
- 2025-10-06 18:18 UTC [SEC Form 25-NSE filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-zyversa-therapeutics-inc-6224406)
- 2025-09-18 11:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-zyversa-therapeutics-inc-6204921)
- 2025-09-10 11:55 UTC [ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes](https://www.quantisnow.com/insight/zyversa-therapeutics-highlights-data-reinforcing-the-potential-of-inflammasome-inhibitors-6195872)
- 2025-08-15 01:25 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-zyversa-therapeutics-inc-6167564)
- 2025-08-13 13:00 UTC [Earnings] [ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones](https://www.quantisnow.com/insight/zyversa-therapeutics-reports-second-quarter-2025-financial-results-and-highlights-6162330)
- 2025-08-13 12:55 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-zyversa-therapeutics-inc-6162317)
- 2025-08-07 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-zyversa-therapeutics-inc-6151873)
- 2025-08-01 21:27 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-zyversa-therapeutics-inc-6143394)
- 2025-07-28 11:55 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6133694)
- 2025-07-21 11:55 UTC [ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress](https://www.quantisnow.com/insight/zyversa-therapeutics-ceo-issues-mid-year-shareholder-letter-highlighting-recent-corporate-6126185)
- 2025-07-18 20:49 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-zyversa-therapeutics-inc-6125688)
- 2025-07-16 16:55 UTC [SEC Form 4] [SEC Form 4 filed by Chief Commercial Officer Cashmere Karen A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-cashmere-karen-6121803)
- 2025-07-16 16:40 UTC [SEC Form 8-K] [SEC Form 8-K filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-zyversa-therapeutics-inc-6121801)
- 2025-07-15 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Director Finizio Robert G](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-finizio-robert-g-6120809)
- 2025-07-15 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Glover Stephen C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-glover-stephen-6120807)
- 2025-07-15 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Guzman Pablo A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-guzman-pablo-6120806)
- 2025-07-15 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Director Freitag Gregory Gene](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-freitag-gregory-gene-6120805)
- 2025-07-15 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Director Sapirstein James](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sapirstein-james-6120804)
- 2025-07-15 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Director Park Min-Chul](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-park-min-chul-6120803)
- 2025-07-15 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Wolfe Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-wolfe-peter-6120802)
- 2025-07-09 20:15 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6115566)
- 2025-07-08 16:30 UTC [ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds](https://www.quantisnow.com/insight/zyversa-therapeutics-announces-a-warrant-inducement-transaction-for-20-million-6114008)
- 2025-07-08 11:52 UTC [ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis](https://www.quantisnow.com/insight/zyversa-therapeutics-supports-fda-authorized-emergency-compassionate-use-of-cholesterol-efflux-6113471)
- 2025-07-02 01:50 UTC [SEC Form S-1] [SEC Form S-1 filed by ZyVersa Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-zyversa-therapeutics-inc-6106957)
- 2025-06-26 11:55 UTC [ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)](https://www.quantisnow.com/insight/zyversa-therapeutics-announces-first-clinical-site-activation-initiating-patient-recruitment-6099804)
- 2025-06-25 13:00 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6098507)
- 2025-06-12 20:47 UTC [SEC Form 8-K] [ZyVersa Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/zyversa-therapeutics-inc-filed-sec-form-8-k-leadership-update-submission-6084252)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ZVSA
- Earnings history: https://www.quantisnow.com/earnings/ZVSA
- Dividend history: https://www.quantisnow.com/dividends/ZVSA
- Insider transactions: https://www.quantisnow.com/insiders/ZVSA
- Options chain: https://www.quantisnow.com/options/ZVSA
- SEC 8-K filings only: https://www.quantisnow.com/company/ZVSA/8-k
- RSS and alerts for ZVSA: https://www.quantisnow.com/docs/rss-feeds.md